Correspondence 0001104659-24-004682 from Accelerate Diagnostics, Inc (AXDX) (CIK 0000727207)
Accelerate Diagnostics, Inc (AXDX) (CIK 0000727207)
Date: Jan. 18, 2024 · CIK: 0000727207 · Accession: 0001104659-24-004682
AI Filing Summary & Sentiment
File numbers found in text: 333-276031
Letter
Re: Accelerate Diagnostics, Inc.
January 18, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Katherine Bagley
Registration Statement on Form S-1
File No. 333-276031
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the representative of the prospective underwriters of the above issuer, hereby join in the request of Accelerate Diagnostics, Inc. (the “Company”) that the effectiveness of the Registration Statement on Form S-1 (Registration No. 333-276031), as amended, be accelerated so that the Registration Statement will become effective at 4:00 p.m. Eastern Time on January 18, 2024, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request by telephone call to the staff of the U.S. Securities and Exchange Commission.
Pursuant to Rule 460 under the Securities Act of 1933, as amended, and in connection with the foregoing, please note that the underwriters have distributed approximately 400 copies of the Company’s preliminary prospectus dated January 16, 2024, through the date hereof, to institutions, prospective underwriters and others.
The undersigned, as the representative of the prospective underwriters of the above issue, hereby represents on behalf of the underwriters that the underwriters are acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering.
[Remainder of Page Intentionally Left Blank; Signature Page Follows]
Very truly yours,
William Blair & Company L.L.C.
Show Raw Text
CORRESP
1
filename1.htm
January 18, 2024
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Katherine Bagley
Re:
Accelerate Diagnostics, Inc.
Registration Statement on Form S-1
File No. 333-276031
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended,
the undersigned, as the representative of the prospective underwriters of the above issuer, hereby join in the request of Accelerate Diagnostics, Inc.
(the “Company”) that the effectiveness of the Registration Statement on Form S-1 (Registration No. 333-276031),
as amended, be accelerated so that the Registration Statement will become effective at 4:00 p.m. Eastern Time on January 18,
2024, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request by telephone call to
the staff of the U.S. Securities and Exchange Commission.
Pursuant to Rule 460 under the Securities Act of 1933, as amended,
and in connection with the foregoing, please note that the underwriters have distributed approximately 400 copies of the Company’s
preliminary prospectus dated January 16, 2024, through the date hereof, to institutions, prospective underwriters and others.
The undersigned, as the representative of the prospective underwriters
of the above issue, hereby represents on behalf of the underwriters that the underwriters are acting in compliance and will act in compliance
with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above
proposed offering.
[Remainder of Page Intentionally Left
Blank; Signature Page Follows]
Very truly yours,
William Blair & Company L.L.C.
By: William Blair & Company L.L.C.
By:
/s/ Steve Maletzky
Name:
Steve Maletzky
Title:
Managing Director
[Signature
Page to Acceleration Request]